Company Overview

Our mission is to improve the lives of people living with diabetes, obesity and other cardiometabolic diseases.

We are applying our proven proprietary technology platform, Arestat®, to develop a portfolio of superior, proprietary products that address areas of high unmet patient need in high value markets.

Our aim is to have multiple options to drive a step-change in company value for our shareholders.

 

Latest Documents

Arecor expands international IP protection for concentrated ultra-rapid acting insulins enabling next generation of AID systems

15 October 2026

Arecor CEO: H1 milestones met and cash runway to 2027 as insulin partnering talks advance

12 October 2026

IMC webcast – half year results 2026

12 October 2026

Contact: ir@arecor.com